13.64
0.26 (1.94%)
| Previous Close | 13.38 |
| Open | 13.30 |
| Volume | 2,159,843 |
| Avg. Volume (3M) | 3,017,334 |
| Market Cap | 1,940,481,024 |
| Price / Book | 3.27 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 3.49% |
| Current Ratio (MRQ) | 20.35 |
| Operating Cash Flow (TTM) | -319.72 M |
| Levered Free Cash Flow (TTM) | -176.84 M |
| Return on Assets (TTM) | -39.92% |
| Return on Equity (TTM) | -64.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Dyne Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.56% |
| % Held by Institutions | 110.24% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Guggenheim, 266.57%) | Buy |
| Median | 32.00 (134.60%) | |
| Low | 9.00 (JP Morgan, -34.02%) | Hold |
| Average | 29.56 (116.72%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 10.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 25 Aug 2025 | 35.00 (156.60%) | Buy | 13.00 |
| 29 Jul 2025 | 31.00 (127.27%) | Buy | 9.20 | |
| Oppenheimer | 06 Aug 2025 | 13.00 (-4.69%) | Buy | 11.59 |
| Stifel | 31 Jul 2025 | 36.00 (163.93%) | Buy | 9.85 |
| Chardan Capital | 29 Jul 2025 | 38.00 (178.59%) | Buy | 9.20 |
| RBC Capital | 29 Jul 2025 | 23.00 (68.62%) | Buy | 9.20 |
| JP Morgan | 15 Jul 2025 | 9.00 (-34.02%) | Hold | 8.28 |
| Jones Trading | 26 Jun 2025 | 30.00 (119.94%) | Buy | 10.05 |
| Baird | 18 Jun 2025 | 32.00 (134.60%) | Buy | 10.78 |
| Guggenheim | 18 Jun 2025 | 50.00 (266.57%) | Buy | 10.78 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COX JOHN | - | 14.22 | -2,640 | -37,541 |
| FRIEDL-NADERER JOHANNA | - | 13.73 | -1,038 | -13,884 |
| KERR DOUGLAS | - | 13.73 | -4,425 | -59,443 |
| Aggregate Net Quantity | -8,103 | |||
| Aggregate Net Value ($) | -110,868 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.83 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KERR DOUGLAS | Officer | 05 Sep 2025 | Automatic sell (-) | 873 | 14.22 | 12,414 |
| FRIEDL-NADERER JOHANNA | Officer | 05 Sep 2025 | Automatic sell (-) | 144 | 14.22 | 2,048 |
| COX JOHN | Officer | 05 Sep 2025 | Automatic sell (-) | 2,640 | 14.22 | 37,541 |
| KERR DOUGLAS | Officer | 04 Sep 2025 | Automatic sell (-) | 3,552 | 13.24 | 47,028 |
| FRIEDL-NADERER JOHANNA | Officer | 04 Sep 2025 | Automatic sell (-) | 894 | 13.24 | 11,837 |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Dyne Therapeutics to Present at Upcoming Investor Conferences |
| 04 Aug 2025 | Announcement | Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) |
| 28 Jul 2025 | Announcement | Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights |
| 02 Jul 2025 | Announcement | Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares |
| 30 Jun 2025 | Announcement | Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock |
| 30 Jun 2025 | Announcement | Dyne Therapeutics Announces Proposed Public Offering of Common Stock |
| 30 Jun 2025 | Announcement | Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |